HBW Market News: CHPA Petitions For CBD Reg, PEW Urges Stronger Supplement Oversight
AHPA releases guidance for tea and infusion products on regulatory and liability implications as a result of increasing Prop 65 lawsuits; CHPA files citizen petition urging FDA to act on a CBD pathway; PEW pushes for stronger supplement oversight; and more.
You may also be interested in...
Busy agenda of disparate topics in one-day meeting likely valuable for informing FDA on safety of hemp ingredients but not for moving toward a regulatory pathway for the ingredients' lawful use in supplements and food.
US CBD Supplement Market Anxious For Lawful Use Proposal, And FDA Offers Cannabis Drug Research Guidance
Adding more cannabis-containing drugs to the three already approved in the US relies on research, but hundreds of supplements and other FDA-regulated non-drug products containing CBDs already are available under enforcement discretion by the agency.
The trade group’s petition is second on a regulation for CBD’s use in non-drug products submitted to FDA and largely tracks with CHPA’s November 2019 petition. Comments continue to reach the FDA after in March it reopened its docket about establishing a CBD regulation, but with little data the agency says is needed for its decision.